OA12276A - A combination kit used in the treatment of malariacontaining chloroquine and 3-(1-(((4-((6-methoxy- 8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3H)furanone enth{lt. - Google Patents

A combination kit used in the treatment of malariacontaining chloroquine and 3-(1-(((4-((6-methoxy- 8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3H)furanone enth{lt. Download PDF

Info

Publication number: OA12276A
Authority: OA; OAPI
Prior art keywords: amino; treatment; malarial; compound; chloroquine
Prior art date: 2000-05-31

Application number

OA1200200359A

Other languages

English (en)

Inventor

Francis Joseph Pinto

Swati Ajay Piramal

Ram Pratap

Original Assignee

Nicholas Piramal India Ltd

Council Scient Ind Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-31

Filing date

2000-08-30

Publication date

2006-05-10

2000-08-30 Application filed by Nicholas Piramal India Ltd, Council Scient Ind Res filed Critical Nicholas Piramal India Ltd

2006-05-10 Publication of OA12276A publication Critical patent/OA12276A/en

Links

238000011282 treatment Methods 0.000 title claims abstract description 40
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 title claims abstract description 27
229960003677 chloroquine Drugs 0.000 title claims abstract description 26
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 title claims abstract description 25
-1 (4-((6-methoxy- 8-quinolinyl)amino)pentyl)amino Chemical group 0.000 title claims description 17
101100118976 Mus musculus Clint1 gene Proteins 0.000 title 1
239000003430 antimalarial agent Substances 0.000 claims abstract description 36
239000002775 capsule Substances 0.000 claims abstract description 32
201000004792 malaria Diseases 0.000 claims abstract description 22
AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 claims abstract description 12
229960002328 chloroquine phosphate Drugs 0.000 claims abstract description 12
239000000463 material Substances 0.000 claims abstract description 9
150000001875 compounds Chemical class 0.000 claims description 36
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 33
229960005179 primaquine Drugs 0.000 claims description 32
INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 claims description 28
125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 17
125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims description 14
108010061951 Methemoglobin Proteins 0.000 claims description 8
206010035503 Plasmodium vivax infection Diseases 0.000 claims description 8
230000000078 anti-malarial effect Effects 0.000 claims description 8
231100000419 toxicity Toxicity 0.000 claims description 7
230000001988 toxicity Effects 0.000 claims description 7
201000009976 Plasmodium vivax malaria Diseases 0.000 claims description 5
208000005469 Vivax Malaria Diseases 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
230000015572 biosynthetic process Effects 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
240000009188 Phyllostachys vivax Species 0.000 claims 3
RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 claims 1
229940125904 compound 1 Drugs 0.000 claims 1
238000012856 packing Methods 0.000 claims 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
241000223810 Plasmodium vivax Species 0.000 abstract description 24
238000011269 treatment regimen Methods 0.000 abstract description 8
ADCOUXIGWFEYJP-UHFFFAOYSA-N 3-[1-[4-[(6-methoxyquinolin-8-yl)amino]pentylamino]ethylidene]oxolan-2-one Chemical compound C=12N=CC=CC2=CC(OC)=CC=1NC(C)CCCNC(C)=C1CCOC1=O ADCOUXIGWFEYJP-UHFFFAOYSA-N 0.000 abstract description 3
229940079593 drug Drugs 0.000 description 14
239000003814 drug Substances 0.000 description 14
241000282693 Cercopithecidae Species 0.000 description 13
230000000694 effects Effects 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
238000000034 method Methods 0.000 description 6
241000223960 Plasmodium falciparum Species 0.000 description 4
239000000203 mixture Substances 0.000 description 4
XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 3
LUBUTTBEBGYNJN-UHFFFAOYSA-N 4-amino-n-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1.COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC LUBUTTBEBGYNJN-UHFFFAOYSA-N 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
229940086269 chloroquine phosphate 500 mg Drugs 0.000 description 3
229960001962 mefloquine Drugs 0.000 description 3
244000045947 parasite Species 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
231100000041 toxicology testing Toxicity 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000224016 Plasmodium Species 0.000 description 2
241000224028 Plasmodium cynomolgi Species 0.000 description 2
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
238000011284 combination treatment Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
231100001231 less toxic Toxicity 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
IOTAOYHKWICOBK-UHFFFAOYSA-N 1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine;3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione;hydrochloride Chemical compound Cl.CC(C)N=C(N)\N=C(/N)NC1=CC=C(Cl)C=C1.O=C1C(=O)C2=CC=CC=C2C(O)=C1C(CC1)CCC1C1=CC=C(Cl)C=C1 IOTAOYHKWICOBK-UHFFFAOYSA-N 0.000 description 1
HQWQVBJUIIJTRE-LKRNKTNVSA-N 4-amino-n-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide;(s)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2r)-piperidin-2-yl]methanol;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine;hydron;chloride Chemical compound Cl.CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1.COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC.C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 HQWQVBJUIIJTRE-LKRNKTNVSA-N 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 1
206010003399 Arthropod bite Diseases 0.000 description 1
241001161843 Chandra Species 0.000 description 1
235000001258 Cinchona calisaya Nutrition 0.000 description 1
241000552118 Cubana Species 0.000 description 1
241000255925 Diptera Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102100035172 Glucose-6-phosphate 1-dehydrogenase Human genes 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 1
LBHLFPGPEGDCJG-UHFFFAOYSA-N N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine Chemical compound COC=1C=C(NC(C)CCCN)C2=NC(OC)=CC(C)=C2C=1OC1=CC=CC(C(F)(F)F)=C1 LBHLFPGPEGDCJG-UHFFFAOYSA-N 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
241001505293 Plasmodium ovale Species 0.000 description 1
239000005030 aluminium foil Substances 0.000 description 1
229960001444 amodiaquine Drugs 0.000 description 1
BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
229960004191 artemisinin Drugs 0.000 description 1
229930101531 artemisinin Natural products 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229960003242 halofantrine Drugs 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
229940080435 lactose 250 mg Drugs 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000005498 polishing Methods 0.000 description 1
229960005385 proguanil Drugs 0.000 description 1
SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
229960000948 quinine Drugs 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
ZISJLHQNEVGTIU-RFEYTNPVSA-M sodium 4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoate Chemical compound [Na+].C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC([O-])=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4 ZISJLHQNEVGTIU-RFEYTNPVSA-M 0.000 description 1
241000894007 species Species 0.000 description 1
210000003046 sporozoite Anatomy 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
229950000856 tafenoquine Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)

OA1200200359A 2000-05-31 2000-08-30 A combination kit used in the treatment of malariacontaining chloroquine and 3-(1-(((4-((6-methoxy- 8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3H)furanone enth{lt. OA12276A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IN501MU2000		2000-05-31

Publications (1)

Publication Number	Publication Date
OA12276A true OA12276A (en)	2006-05-10

Family

ID=11097250

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200359A OA12276A (en)	2000-05-31	2000-08-30	A combination kit used in the treatment of malariacontaining chloroquine and 3-(1-(((4-((6-methoxy- 8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3H)furanone enth{lt.

Country Status (28)

Country	Link
US (1)	US7404962B1 (de)
EP (1)	EP1292306B1 (de)
JP (1)	JP2004505017A (de)
KR (1)	KR20030025926A (de)
AP (1)	AP1435A (de)
AR (1)	AR028458A1 (de)
AT (1)	ATE314848T1 (de)
AU (2)	AU2879001A (de)
BR (1)	BR0005247A (de)
CA (1)	CA2413775C (de)
CR (1)	CR6835A (de)
CZ (1)	CZ296875B6 (de)
DE (2)	DE00993875T1 (de)
DK (1)	DK1292306T3 (de)
EC (1)	ECSP003694A (de)
ES (1)	ES2200729T3 (de)
GT (1)	GT200000187A (de)
HK (1)	HK1052467B (de)
HN (1)	HN2001000118A (de)
HU (1)	HUP0301925A3 (de)
MX (1)	MXPA02011883A (de)
NO (1)	NO324774B1 (de)
OA (1)	OA12276A (de)
PE (1)	PE20011319A1 (de)
PL (1)	PL200748B1 (de)
SV (1)	SV2002000201A (de)
WO (1)	WO2001091535A2 (de)
ZA (1)	ZA200209726B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007098047A2 (en) *	2006-02-16	2007-08-30	The Mclean Hospital Corporation	Methods and compositions for the treatment of parkinson's disease
EP2379505A4 (de) *	2008-12-05	2012-10-17	Designmedix Inc	Modifizierte chloroquine mit einzelringeinheit oder kondensierter ringeinheit
WO2010144102A1 (en) *	2009-06-09	2010-12-16	The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Material Command	Pentafluorosulfanyl analogs of mefloquine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4431807A (en) *	1980-06-12	1984-02-14	The United States Of America As Represented By The Secretary Of The Army	4-Methyl-5-(unsubstituted and substituted phenoxy)-6-methoxy-8-(aminoalkylamino)quinolines
US5219865A (en) *	1987-05-08	1993-06-15	Hoechst Aktiengesellschaft	Pharmaceutical combination for the prophylaxis and therapy of malaria
US5373005A (en) *	1988-04-20	1994-12-13	Merrell Dow Pharmaceuticals Inc.	Despiramine in the treatment of drug-resistant malarial infections
US5270037A (en) *	1990-07-12	1993-12-14	Boehringer Ingelheim Gmbh	Use of interferon and a substance with an antimalarial activity for the treatment of malaria infections
FI934360A0 (fi) *	1992-02-07	1993-10-04	Ciba Geigy Ag	Synergistiska antimalariakompositioner innehaollande benflumetol

2000
- 2000-08-30 DK DK00993875T patent/DK1292306T3/da active
- 2000-08-30 US US10/296,215 patent/US7404962B1/en not_active Expired - Fee Related
- 2000-08-30 HU HU0301925A patent/HUP0301925A3/hu unknown
- 2000-08-30 MX MXPA02011883A patent/MXPA02011883A/es active IP Right Grant
- 2000-08-30 ES ES00993875T patent/ES2200729T3/es not_active Expired - Lifetime
- 2000-08-30 JP JP2001587559A patent/JP2004505017A/ja active Pending
- 2000-08-30 HK HK03104811.6A patent/HK1052467B/en not_active IP Right Cessation
- 2000-08-30 AU AU2879001A patent/AU2879001A/xx active Pending
- 2000-08-30 DE DE0001292306T patent/DE00993875T1/de active Pending
- 2000-08-30 WO PCT/IN2000/000081 patent/WO2001091535A2/en not_active Ceased
- 2000-08-30 DE DE60025403T patent/DE60025403T2/de not_active Expired - Lifetime
- 2000-08-30 CA CA002413775A patent/CA2413775C/en not_active Expired - Fee Related
- 2000-08-30 CZ CZ20024071A patent/CZ296875B6/cs not_active IP Right Cessation
- 2000-08-30 OA OA1200200359A patent/OA12276A/en unknown
- 2000-08-30 AP APAP/P/2002/002672A patent/AP1435A/en active
- 2000-08-30 KR KR1020027016169A patent/KR20030025926A/ko not_active Ceased
- 2000-08-30 PL PL372718A patent/PL200748B1/pl not_active IP Right Cessation
- 2000-08-30 EP EP00993875A patent/EP1292306B1/de not_active Expired - Lifetime
- 2000-08-30 AU AU2001228790A patent/AU2001228790B2/en not_active Ceased
- 2000-08-30 AT AT00993875T patent/ATE314848T1/de active
- 2000-10-05 EC EC2000003694A patent/ECSP003694A/es unknown
- 2000-10-13 SV SV2000000201A patent/SV2002000201A/es unknown
- 2000-10-25 GT GT200000187A patent/GT200000187A/es unknown
- 2000-11-06 BR BR0005247-7A patent/BR0005247A/pt not_active Application Discontinuation
2001
- 2001-05-14 AR ARP010102288A patent/AR028458A1/es unknown
- 2001-05-23 PE PE2001000469A patent/PE20011319A1/es not_active Application Discontinuation
- 2001-05-30 HN HN2001000118A patent/HN2001000118A/es unknown
2002
- 2002-11-28 CR CR6835A patent/CR6835A/es not_active Application Discontinuation
- 2002-11-29 ZA ZA200209726A patent/ZA200209726B/en unknown
- 2002-11-29 NO NO20025765A patent/NO324774B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU2001228790B2 (en)	2007-02-01
AR028458A1 (es)	2003-05-07
PE20011319A1 (es)	2002-03-02
SV2002000201A (es)	2002-10-24
ZA200209726B (en)	2004-03-10
NO20025765L (no)	2003-01-08
HK1052467B (en)	2006-03-10
NO324774B1 (no)	2007-12-10
CZ20024071A3 (cs)	2003-04-16
WO2001091535A2 (en)	2001-12-06
ES2200729T1 (es)	2004-03-16
HUP0301925A3 (en)	2009-03-30
AU2879001A (en)	2001-12-11
PL372718A1 (en)	2005-07-25
DE60025403T2 (de)	2006-08-24
HK1052467A1 (en)	2003-09-19
ECSP003694A (es)	2002-01-25
CA2413775A1 (en)	2001-12-06
GT200000187A (es)	2002-04-18
CZ296875B6 (cs)	2006-07-12
DE60025403D1 (de)	2006-03-30
US7404962B1 (en)	2008-07-29
HUP0301925A2 (hu)	2003-09-29
PL200748B1 (pl)	2009-02-27
DK1292306T3 (da)	2006-05-22
KR20030025926A (ko)	2003-03-29
AP1435A (en)	2005-06-21
WO2001091535B1 (en)	2002-10-31
CR6835A (es)	2007-04-26
EP1292306A2 (de)	2003-03-19
BR0005247A (pt)	2002-02-13
MXPA02011883A (es)	2004-05-17
ES2200729T3 (es)	2006-07-16
AP2002002672A0 (en)	2002-12-31
EP1292306B1 (de)	2006-01-04
ATE314848T1 (de)	2006-02-15
HN2001000118A (es)	2001-10-29
WO2001091535A3 (en)	2002-07-04
DE00993875T1 (de)	2004-04-15
CA2413775C (en)	2009-08-25
NO20025765D0 (no)	2002-11-29
JP2004505017A (ja)	2004-02-19

Publication	Publication Date	Title
KR20040029360A (ko)	2004-04-06	Ｄ-트레오메틸페니데이트로 인지 장애 및 폐경기 장애를치료하는 방법
Looareesuwan et al.	1987	Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers.
CA2664935A1 (en)	2008-04-03	Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
US20060229293A1 (en)	2006-10-12	Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
Looareesuwan et al.	1996	Treatment of acute, uncomplicated, falciparum malaria with oral dihydroartemisinin
Cassano et al.	1998	The panic-agoraphobic spectrum: rationale, assessment, and clinical usefulness
US20050043274A1 (en)	2005-02-24	Pharmaceutical compositions and methods for lowering blood pressure and pulse rate
CA2028514C (en)	1995-02-07	Treatment of depression
TWI402071B (zh)	2013-07-21	用於治療嚴重瘧疾之雙噻唑鎓鹽或其前驅物與青蒿素或其衍生物之組合
AU2001228790B2 (en)	2007-02-01	A combination kit used in the treatment of malaria containing chloroquine and 3-(1-(((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3H)furanone enthalt
JP6087988B2 (ja)	2017-03-01	鼻汁分泌抑制用組成物
CN104546828B (zh)	2017-11-14	丁基苯酞或其衍生物在制备治疗或预防糖尿病并发症的药物中的应用
Ojewole	1976	Studies on the pharmacology of some antimalarial drugs
US3714365A (en)	1973-01-30	Reducing abnormally high plasma lipid levels in mammals with phenols
Alvar et al.	1987	In vitro chloroquine-resistant falciparum malaria in Malabo, Equatorial Guinea
JP2018177773A (ja)	2018-11-15	医薬
Chang	2018	Artemisinins and Pyronaridine Phosphate Combination
JP2807535B2 (ja)	1998-10-08	白内障治療剤
UA145542U (uk)	2020-12-28	Спосіб лікування інфекційних захворювань
Folb et al.	1970	Drugs Used in Tropical Medicine
Murgatroyd	1952	The chemotherapy of malaria
UA145352U (uk)	2020-12-10	Готовий лікарський засіб для симптоматичного лікування або запобігання застуди або грипу
Ashinsky	1992	Hemochromatosis: It's more than skin-deep
Pacifici	2018	Clinical Pharmacology of the Antimalarial Proguanil in Infants and Children
Stuppy	1954	HEXAMETHONIUM AND HYDRALAZINE HYDROCHLORIDE—For Treatment of Hypertension